NovaVax 89% prevention effect… Effects of mutations originating in South Africa ↓
[뉴스리뷰]
[앵커]
It was found that the vaccine developed by the US pharmaceutical company NovaVax showed 89% preventive effect against COVID-19.
Following the achievements of Pfizer, Moder, and vaccines, this is promising news for the whole world seeking collective immunity.
However, it is pointed out that this vaccine also needs to be enhanced as it appears to be somewhat ineffective against mutations in South Africa.
This is reporter Jinwoo Lee.
[기자]
As a result of NovaVax’s Phase 3 clinical trial for the COVID-19 vaccine, it showed 89.3% prevention effect.
In particular, 1 out of 4 participants in this clinical trial is 65 years of age or older, and has proven its effectiveness in the elderly.
NovaVax’s vaccine also prevented 85.6% of the COVID-19 mutant virus that is currently prevalent in the UK.
The problem is that the immune effect against mutant viruses from South Africa is somewhat inferior.
In this clinical trial, the preventive effect against mutations from South Africa was 60%.
Pfizer, modder, and vaccines, which had previously shown more than 90% of the preventive effects, were found to be ineffective against mutant viruses from South Africa, and the current vaccine update work has begun to increase its effectiveness.
For this reason, in Europe, vaccines are not supplied in time, and supply and demand are difficult.
This is why it is pointed out that it is necessary to prepare a detailed vaccination schedule, considering the fact that research on the mutant virus takes 2-3 months.
<정기석 / 한림대성심병원 호흡기내과 교수> “Even the production company doesn’t know how to supply it. Isn’t there a production disruption? That’s the problem, as Commissioner Eun-kyung Jung said, it’s all come in one after another by September, and it’s all right and the first dose is finished.
Currently, Korea has secured vaccines for 56 million people from four pharmaceutical companies, including Pfizer, Modena, AstraZeneca, and Janssen.
In addition, the government is negotiating with NovaVax to purchase an additional 20 million people, and plans to introduce it in May when the contract is signed to minimize uncertainty in the supply and demand of vaccines.
This is Yonhap News TV, Lee Jin-woo. ([email protected])
Yonhap News TV article inquiries and reports: katok/line jebo23
(End)